Trinity Biotech launches Trinovium liquid cooling subsidiary

• Trinity Biotech (NASDAQ:TRIB) launched Trinovium, a new subsidiary focused on advanced liquid cooling fluids and intelligence systems for AI data centers.
• Trinovium targets the liquid cooling market, forecast to grow from $4 billion in 2026 to $27 billion by 2033.
• The subsidiary leverages Trinity Biotech’s high-purity manufacturing expertise while the company continues to advance its core diagnostic products.

Trinity Biotech (NASDAQ:TRIB) launched Trinovium, a subsidiary dedicated to advanced liquid cooling fluids and intelligence systems for AI and high-performance computing data centers.

Trinovium will focus on the rapidly expanding data center liquid cooling market, which is projected to grow from $4 billion in 2026 to $27 billion by 2033 at a 31.5% compound annual growth rate.

Initial products include a direct-to-chip coolant featuring ultra-high purity, corrosion protection, and healthcare-grade consistency, supported by Trinity Biotech’s existing US and EU high-purity fluid manufacturing and analytics capabilities.

The subsidiary also plans to introduce a fluid health monitoring platform.

Trinity Biotech continues to commercialize its FDA 510(k)-cleared diabetes and hemoglobin analyzers, WHO-prequalified HIV tests, and develop its CGM+ continuous glucose monitoring solution.

Trinity Biotech operates in both the medical diagnostics space and, now, the high-growth AI infrastructure cooling sector through its new subsidiary.

The company aims to capitalize on strong demand for efficient cooling solutions as data centers scale to support artificial intelligence workloads.